Screener
UroGen Pharma URGN Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: UroGen Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 8:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025794
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 19) | ||
| Shareholders' deficit: | ||
| Ordinary shares, NIS 0.01 par value, 100,000,000 shares authorized at June 30, 2026 and December 31, 2025; 48,869,530 and 48,350,272 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 135 | 133 |
| Additional paid-in capital | 865,112 | 854,090 |
| Accumulated deficit | (997,641) | (959,716) |
| Accumulated other comprehensive income | (2) | 19 |
| Total shareholders' deficit | (132,396) | (105,474) |
| Total liabilities and shareholders' deficit | $252,590 | $200,455 |
Item 1. Financial Statements.
FAQ
- What is UroGen Pharma's total liabilities & equity?
- UroGen Pharma (URGN) reported total liabilities & equity of $252.59M in Q2 2026.
- How has UroGen Pharma's total liabilities & equity changed year-over-year?
- UroGen Pharma's total liabilities & equity increased by 21.0% year-over-year, from $208.72M to $252.59M.
- What is the long-term trend for UroGen Pharma's total liabilities & equity?
- Over 5 years (2020 to 2025), UroGen Pharma's total liabilities & equity has grown at a 10.4% compound annual growth rate (CAGR), from $122.01M to $200.46M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about UroGen Pharma's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude